LAKE FOREST, Ill., April 27, 2023 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release first quarter 2023 financial results on Tuesday, May 9, 2023, after the market close. Following the release of its financial results, Assertio’s management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.
To access the live webcast, conference call information, and other materials, please visit Assertio’s investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. For those wishing to join by telephone only, please dial +1-929-201-5912.
A webcast replay of the call will be available approximately two hours after the call on Assertio’s investor website.
About Assertio
Assertio is a specialty pharmaceutical company offering differentiated products to patients utilizing a non-personal promotional model. We have built and continue to build our commercial portfolio by identifying new opportunities within our existing products as well as acquisitions or licensing of additional approved products. To learn more about Assertio, visit www.assertiotx.com.
Investor Contact
Matt Kreps
Darrow Associates Investor Relations
+1-214-597-8200
mkreps@darrowir.com
– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of…
Oslo, 24 May 2025: Zelluna ASA (the "Company") refers to the resolution by the Company's…
Los Angeles, CA and Vancouver, BC, May 23, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc.…
$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon…
INDIANAPOLIS, May 23, 2025 /PRNewswire/ -- This Memorial Day Weekend, the spotlight won't only be on…
IRVING, Texas, May 23, 2025 /PRNewswire/ -- Caris Life Sciences® ("Caris"), a leading, patient-centric, next-generation AI…